Pharmaceutical company
Appears in 11 stories
Sponsor of remigromig development
Merck presented full one-year results from its 984-patient BRUNELLO trial at the American Academy of Ophthalmology meeting on October 10. Both remigromig doses met the primary endpoint, with visual acuity gains of +9.1 and +8.7 letters versus +11.8 for ranibizumab at 52 weeks. But the trial showed higher rates of proliferative diabetic retinopathy (6.7% and 6.1% versus 0.9%) and treatment discontinuations in the remigromig arms, and no secondary endpoint beat ranibizumab.
Updated Yesterday
Maker of Capvaxive, a comparator in OPUS-1
Vaxcyte said Monday its experimental pneumococcal vaccine met every primary goal in the first of three late-stage trials. VAX-31, which targets 31 strains of the bacteria behind pneumonia and meningitis, matched Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all shared strains, beat both on three strains only it covers, and sent shares up roughly 50% to push the company's market value past $12 billion.
Updated 5 days ago
Co-developer of ifinatamab deruxtecan
Merck and Daiichi Sankyo withdrew their US application for ifinatamab deruxtecan, an experimental antibody-drug conjugate for extensive-stage small cell lung cancer, an aggressive disease that has resisted most new treatments. The FDA had told the companies their Phase 2 data were not enough to support accelerated approval, and the bid was pulled on September 25.
Updated Sep 29
Manufacturer of the Ervebo vaccine
Congo's frontline health workers are getting the only Ebola vaccine available at scale, even though it was built for a different virus. Since September 19, the BRAVO study has been vaccinating 20,000 workers in Ituri and North Kivu to test whether Ervebo protects against the Bundibugyo strain.
Updated Sep 20
Developer and seller of Lipfendra
For a decade, the most powerful cholesterol drugs came only as shots. On July 16, 2026, the FDA approved Merck's Lipfendra, a once-daily pill that cut LDL cholesterol about as much as those injections did.
Updated Jul 16
Maker of both belzutifan (Welireg) and pembrolizumab (Keytruda)
Surgery removes the tumor. For many high-risk kidney cancer patients, it doesn't end the disease. On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved pairing belzutifan with the immunotherapy pembrolizumab to keep these patients cancer-free for longer after their kidney is removed.
Updated Jun 12
Advancing enlicitide decanoate toward FDA filing after positive Phase 3 results
For two decades, lowering LDL cholesterol meant statins—daily pills that work for most but leave roughly one in five patients with muscle pain or liver enzyme changes severe enough to quit. On May 1, researchers from the University of Barcelona and Oregon Health & Science University reported that engineered DNA reduced LDL by nearly 50 percent in mice. A single injection of this engineered DNA molecule silences the gene controlling how the liver clears LDL.
Updated May 31
Acquirer — executing multiyear pipeline-rebuilding strategy
Keytruda, the world's best-selling drug, generated $31.7 billion for Merck in 2025 — roughly 40% of the company's total revenue. Its key U.S. patents expire in 2028, and when they do, cheaper copies will enter the market and that revenue will begin to evaporate. Merck has now spent over $25 billion on three acquisitions in nine months to build the portfolio that will need to replace it.
Updated May 30
Co-developer and commercialization partner
Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit until now.
Updated May 22
Active acquirer, refinancing biotech purchases in debt markets
Merck borrowed billions in the investment-grade bond market on Monday. The cash refinances its $6.7 billion all-cash purchase of Terns Pharmaceuticals, a small California biotech the company closed on two weeks ago.
Updated May 18
Expanding infectious disease portfolio through $9.2B Cidara acquisition
Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles vaccine in development. The 39% premium signals desperation in a market projected to hit $37.2 billion by 2033, driven by aging populations; the deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance.[1] By 2050, 2.1 billion people will be over 60, triple the population over 80.
Updated May 16
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
